BIOMAT Database Logo BIOMAT Database Logo

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. 1990

R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research Facility, MD 21701.

We evaluated the toxic, hematopoietic, and immunomodulatory effects of recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF). The rHuGM-CSF was administered at doses up to 50 micrograms/kg by daily 2-hour intravenous infusions to 11 patients with advanced malignancy. It induced dose-related increases in cells of the myeloid series, but it had no significant effect on reticulocyte or platelet counts. Bone marrow cellularity increased with higher doses of rHuGM-CSF, but there was a dose-related decrease in the number of colony-forming units--granulocyte-monocyte--and colony-forming units--granulocyte-erythrocyte-monocyte-megakaryocyte--per 10(5) bone marrow cells. The rHuGM-CSF caused transient increased expression of CD11b and CD16 on granulocytes but increased expression of HLA-DR and decreased expression of the high-affinity Fc receptor on monocytes and no change in monocyte production of H2O2. Thus, rHuGM-CSF has potent effects on granulocyte, eosinophil, and monocyte numbers in the peripheral blood and bone marrow. In addition, it enhances the expression of monocyte and granulocyte activation-associated surface markers.

UI MeSH Term Description Entries
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011961 Receptors, Fc Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules. Fc Receptors,Fc Receptor,Receptor, Fc
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D003115 Colony-Stimulating Factors Glycoproteins found in a subfraction of normal mammalian plasma and urine. They stimulate the proliferation of bone marrow cells in agar cultures and the formation of colonies of granulocytes and/or macrophages. The factors include INTERLEUKIN-3; (IL-3); GRANULOCYTE COLONY-STIMULATING FACTOR; (G-CSF); MACROPHAGE COLONY-STIMULATING FACTOR; (M-CSF); and GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; (GM-CSF). MGI-1,Macrophage-Granulocyte Inducer,Colony Stimulating Factor,Colony-Stimulating Factor,MGI-1 Protein,Myeloid Cell-Growth Inducer,Protein Inducer MGI,Cell-Growth Inducer, Myeloid,Colony Stimulating Factors,Inducer, Macrophage-Granulocyte,Inducer, Myeloid Cell-Growth,MGI 1 Protein,MGI, Protein Inducer,Macrophage Granulocyte Inducer,Myeloid Cell Growth Inducer
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006098 Granulocytes Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS. Granulocyte
D006133 Growth Substances Signal molecules that are involved in the control of cell growth and differentiation. Mitogens, Endogenous,Endogenous Mitogens

Related Publications

R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.
February 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
[Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors].
May 1993, Bulletin du cancer,
R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy.
March 1989, Annals of internal medicine,
R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial.
January 1989, Blood,
R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase-I/II trial.
February 1988, Onkologie,
R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. The Multicenter Study Group.
January 1992, Acta haematologica,
R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor.
April 1989, Seminars in hematology,
R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
August 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy.
August 1988, Behring Institute Mitteilungen,
R G Steis, and L A VanderMolen, and D L Longo, and J W Clark, and J W Smith, and W C Kopp, and F W Ruscetti, and S P Creekmore, and L J Elwood, and J Hursey
Recombinant human granulocyte-macrophage colony-stimulating factor in AIDS.
March 1988, The New England journal of medicine,
Copied contents to your clipboard!